Medpace Holdings Inc (MEDP)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $18.29B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medpace Holdings Inc (MEDP) Earnings: Report Dates and Results
Medpace Holdings (MEDP) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Medpace Holdings reported EPS of $4.84, above the $4.45 estimate. It beat the EPS estimate in each of the last 13 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MEDP has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 5.6% above the $4.67 reported for the quarter ended Dec 31, 2025.
MEDP Earnings Call
The latest MEDP earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MEDP beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $716.00M, up 8.5% from $659.90M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.84 | $4.45 | $4.31 - $4.69 | +8.76% | Beat | +25.4% | 8 | 1 up, 0 down | Oct 21, 2026 | $716.00M |
| Jun 30, 2026 | $4.25 | $4.08 | $3.71 - $4.35 | +4.17% | Beat | +37.1% | 9 | 3 up, 5 down | Jul 22, 2026 | $707.33M |
| Mar 31, 2026 | $4.28 | $3.96 | $3.47 - $4.40 | +8.08% | Beat | +16.6% | 8 | 1 up, 0 down | Apr 22, 2026 | $706.60M |
| Dec 31, 2025 | $4.67 | $4.18 | $4.12 - $4.37 | +11.72% | Beat | +26.9% | 5 | 0 up, 1 down | Feb 9, 2026 | $708.45M |
| Sep 30, 2025 | $3.86 | $3.57 | $3.38 - $3.66 | +8.12% | Beat | +28.2% | 6 | 2 up, 0 down | Oct 22, 2025 | $659.90M |
| Jun 30, 2025 | $3.10 | $3.00 | $2.76 - $3.28 | +3.33% | Beat | +12.3% | 6 | 1 up, 2 down | Jul 21, 2025 | $603.31M |
| Mar 31, 2025 | $3.67 | $3.07 | $3.00 - $3.28 | +19.54% | Beat | +14.0% | 4 | 1 up, 1 down | Apr 21, 2025 | $558.57M |
| Dec 31, 2024 | $3.68 | $3.12 | $3.09 - $3.17 | +18.12% | Beat | +49.6% | 3 | 2 up, 0 down | Feb 10, 2025 | $536.59M |
| Sep 30, 2024 | $3.01 | $2.87 | N/A | +4.88% | Beat | +34.4% | 8 | 0 up, 2 down | Oct 21, 2024 | $533.32M |
| Jun 30, 2024 | $2.76 | $2.63 | N/A | +4.94% | Beat | +41.5% | 8 | 1 up, 0 down | Jul 22, 2024 | $528.10M |
| Mar 31, 2024 | $3.22 | $2.49 | $2.43 - $2.54 | +29.32% | Beat | +41.2% | 6 | 0 up, 0 down | Apr 22, 2024 | $511.04M |
| Dec 31, 2023 | $2.46 | $2.22 | $2.20 - $2.25 | +10.81% | Beat | +16.0% | 5 | 0 up, 0 down | Feb 12, 2024 | $498.40M |
| Sep 30, 2023 | $2.24 | $2.19 | N/A | +2.28% | Beat | +8.2% | 5 | 1 up, 0 down | Oct 23, 2023 | $492.50M |
| Jun 30, 2023 | $1.95 | $2.00 | N/A | -2.50% | Miss | +31.8% | 5 | 1 up, 0 down | Jul 24, 2023 | $460.87M |
| Mar 31, 2023 | $2.28 | $1.88 | N/A | +21.28% | Beat | +33.3% | 4 | 0 up, 0 down | Apr 24, 2023 | $434.07M |
| Dec 31, 2022 | $2.12 | $1.79 | $1.74 - $1.82 | +18.44% | Beat | +60.6% | 5 | 0 up, 0 down | Feb 13, 2023 | $394.10M |
| Sep 30, 2022 | $2.07 | $1.54 | N/A | +34.42% | Beat | +56.8% | 5 | 1 up, 0 down | Oct 24, 2022 | $383.74M |
| Jun 30, 2022 | $1.48 | $1.39 | $1.16 - $1.42 | +6.47% | Beat | +35.8% | 5 | 1 up, 1 down | Jul 25, 2022 | $351.21M |
| Mar 31, 2022 | $1.71 | $1.31 | N/A | +30.53% | Beat | +44.9% | 4 | 0 up, 0 down | Apr 25, 2022 | $330.95M |
| Dec 31, 2021 | $1.32 | $1.25 | $1.22 - $1.27 | +5.60% | Beat | -2.2% | 4 | 0 up, 0 down | Feb 14, 2022 | $308.55M |
| Sep 30, 2021 | $1.32 | $1.12 | N/A | +17.86% | Beat | +15.8% | 4 | N/A | Oct 25, 2021 | $295.57M |
| Jun 30, 2021 | $1.09 | $1.03 | $0.97 - $1.04 | +5.83% | Beat | +60.3% | 6 | N/A | Jul 26, 2021 | $278.29M |
| Mar 31, 2021 | $1.18 | $1.07 | N/A | +10.28% | Beat | +47.5% | 6 | N/A | Apr 26, 2021 | $259.96M |
| Dec 31, 2020 | $1.35 | $1.24 | $1.20 - $1.30 | +8.87% | Beat | +58.8% | 6 | N/A | Feb 15, 2021 | $259.68M |
| Sep 30, 2020 | $1.14 | $1.16 | N/A | -1.72% | Miss | +60.6% | 6 | N/A | Oct 26, 2020 | $230.37M |
| Jun 30, 2020 | $0.68 | $0.44 | $0.19 - $0.54 | +54.55% | Beat | -16.0% | 7 | N/A | Jul 27, 2020 | $205.00M |
| Mar 31, 2020 | $0.80 | $0.75 | $0.69 - $0.83 | +6.67% | Beat | +25.0% | 4 | N/A | Apr 28, 2020 | $230.88M |
| Dec 31, 2019 | $0.85 | $0.75 | $0.74 - $0.76 | +13.33% | Beat | +11.8% | 6 | N/A | Feb 24, 2020 | $229.89M |
| Sep 30, 2019 | $0.71 | $0.71 | $0.64 - $0.75 | 0.00% | In line | +6.0% | 6 | N/A | Oct 28, 2019 | $216.24M |
| Jun 30, 2019 | $0.81 | $0.64 | $0.58 - $0.81 | +26.56% | Beat | +32.8% | 6 | N/A | Jul 29, 2019 | $214.10M |
| Mar 31, 2019 | $0.64 | $0.61 | $0.54 - $0.65 | +4.92% | Beat | +16.4% | 7 | N/A | Apr 29, 2019 | $200.74M |
| Dec 31, 2018 | $0.76 | $0.67 | $0.60 - $0.73 | +13.43% | Beat | +94.9% | 5 | N/A | Feb 25, 2019 | $192.12M |
| Sep 30, 2018 | $0.67 | $0.63 | $0.59 - $0.65 | +6.35% | Beat | +67.5% | 5 | N/A | Oct 29, 2018 | $179.25M |
| Jun 30, 2018 | $0.61 | $0.43 | $0.36 - $0.45 | +41.86% | Beat | +60.5% | 7 | N/A | Jul 30, 2018 | $170.14M |
| Mar 31, 2018 | $0.55 | $0.44 | $0.42 - $0.45 | +25.00% | Beat | +61.8% | 7 | N/A | Apr 30, 2018 | $163.08M |
| Dec 31, 2017 | $0.39 | $0.38 | $0.37 - $0.41 | +2.63% | Beat | +11.4% | 7 | N/A | Feb 26, 2018 | $112.68M |
| Sep 30, 2017 | $0.40 | $0.36 | $0.35 - $0.37 | +11.11% | Beat | 0.0% | 7 | N/A | Oct 30, 2017 | $110.64M |
| Jun 30, 2017 | $0.38 | $0.30 | $0.29 - $0.31 | +26.67% | Beat | -15.6% | 6 | N/A | Jul 31, 2017 | $106.22M |
| Mar 31, 2017 | $0.34 | $0.37 | N/A | -8.11% | Miss | N/A | N/A | N/A | May 1, 2017 | $106.61M |
| Dec 31, 2016 | $0.35 | $0.34 | N/A | +2.94% | Beat | N/A | N/A | N/A | Feb 27, 2017 | $108.24M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $15.30, up 20.7% from the year before. It was $1.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $15.30 | +20.7% |
| Dec 31, 2024 | $12.67 | +41.9% |
| Dec 31, 2023 | $8.93 | +21.0% |
| Dec 31, 2022 | $7.38 | +50.3% |
| Dec 31, 2021 | $4.91 | +23.7% |
| Dec 31, 2020 | $3.97 | +31.9% |
| Dec 31, 2019 | $3.01 | +16.2% |
| Dec 31, 2018 | $2.59 | +71.5% |
| Dec 31, 2017 | $1.51 | +25.8% |
| Dec 31, 2016 | $1.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,198 | 14 | |
| 2026Q2 | Jun 30, 2026 | 4,401 | 14 | |
| 2026Q1 | Mar 31, 2026 | 5,108 | 16 | |
| 2025Q4 | Dec 31, 2025 | 5,609 | 16 | |
| 2025Q3 | Sep 30, 2025 | 5,060 | 15 | |
| 2025Q2 | Jun 30, 2025 | 6,714 | 15 | |
| 2025Q1 | Mar 31, 2025 | 5,850 | 14 | |
| 2024Q4 | Dec 31, 2024 | 4,929 | 14 |
2026Q3 Earnings Call
Opening remarks
Lauren Morris Director of Investor Relations Good morning, and thank you for joining Medpace's third quarter 2026 Earnings Conference Call. Also on the call today are our CEO, August James Troendle, and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2000. These statements involve inherent assumptions, with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-Ks and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements, even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the Investor Relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Troendle.
August James Troendle CEO Thanks, Lauren. Good morning, everyone. The business environment remains strong in the third quarter of 2026. We saw high-quality RFP activity, strong initial award notifications, and a good win rate. Net new business awards reached an all-time high in the quarter, and our last 12-month closing awards growth was 23.9%. We will provide guidance for 2027 at the end of our Q4 reporting. At the time of our Q4 reporting in February, however, we see no large disconnect between analyst consensus estimates and our current modeling of 2027. Kevin will now review our financial results for Q3 and our updated 2026 guidance.
Kevin Brady CFO Thank you, and good morning to everyone listening in. Revenue was $716 million in the third quarter of 2026. This represented a year-over-year increase of 8.5%. Revenue for the nine months ended September 30, 2026, was $2.13 billion, an increase of 16.9%. EBITDA of $172.1 million increased 16% compared to $148.4 million in the third quarter of 2025. Year-to-date EBITDA was $474.9 million, an increase of 19.5% from the comparable prior-year period. EBITDA margin for the third quarter was 24%, compared to 22.5% in the prior-year period. EBITDA margins benefited from lower reimbursable costs.
Frequently Asked Questions About MEDP
When is Medpace Holdings's next earnings date?
Medpace Holdings's next earnings report is expected for Feb 8, 2027.
Did MEDP beat earnings estimates last quarter?
Yes. Medpace Holdings reported EPS of $4.84 for the quarter ended Sep 30, 2026, above the $4.45 estimate, a 8.76% surprise.
What EPS do analysts expect from MEDP next quarter?
The consensus EPS estimate for Medpace Holdings for the quarter ending Dec 31, 2026 is $4.93 from 14 analysts, with estimates from $4.67 to $5.20.
How often does MEDP beat earnings estimates?
Medpace Holdings beat the EPS estimate in each of the last 13 quarters, with an average surprise of +10.31%.
MEDP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors